Niagen Bioscience annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Niagen Bioscience's gross margin was 64.28% for fiscal 2025.
View full Niagen Bioscience company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 64.28% | +2.44 pp |
| 2024 | 2024-12-31 | 61.84% | +1.07 pp |
| 2023 | 2023-12-31 | 60.76% | +1.36 pp |
| 2022 | 2022-12-31 | 59.40% | −2.11 pp |
| 2021 | 2021-12-31 | 61.51% | +1.99 pp |
| 2020 | 2020-12-31 | 59.53% | +3.86 pp |
| 2019 | 2019-12-31 | 55.67% | +4.79 pp |
| 2018 | 2018-12-31 | 50.88% | +1.46 pp |
| 2017 | 2017-12-30 | 49.42% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 64.84% | −0.16 pp |
| Q1 2026 | 2026-03-31 | 63.47% | +0.05 pp |
| Q4 2025 | 2025-12-31 | 64.14% | +1.66 pp |
| Q3 2025 | 2025-09-30 | 64.52% | +1.03 pp |
| Q2 2025 | 2025-06-30 | 65.00% | +4.78 pp |
| Q1 2025 | 2025-03-31 | 63.42% | +2.68 pp |
| Q4 2024 | 2024-12-31 | 62.48% | +1.44 pp |
| Q3 2024 | 2024-09-30 | 63.49% | +2.09 pp |
| Q2 2024 | 2024-06-30 | 60.22% | −0.58 pp |
| Q1 2024 | 2024-03-31 | 60.74% | +0.81 pp |
| Q4 2023 | 2023-12-31 | 61.04% | +3.81 pp |
| Q3 2023 | 2023-09-30 | 61.40% | +1.58 pp |
| Q2 2023 | 2023-06-30 | 60.80% | +0.78 pp |
| Q1 2023 | 2023-03-31 | 59.93% | −1.09 pp |
| Q4 2022 | 2022-12-31 | 57.23% | −3.97 pp |
| Q3 2022 | 2022-09-30 | 59.82% | −1.30 pp |
| Q2 2022 | 2022-06-30 | 60.02% | −1.06 pp |
| Q1 2022 | 2022-03-31 | 61.02% | −1.87 pp |
| Q4 2021 | 2021-12-31 | 61.20% | +0.20 pp |
| Q3 2021 | 2021-09-30 | 61.12% | +1.50 pp |
| Q2 2021 | 2021-06-30 | 61.08% | +1.63 pp |
| Q1 2021 | 2021-03-31 | 62.89% | +4.95 pp |
| Q4 2020 | 2020-12-31 | 61.00% | +3.96 pp |
| Q3 2020 | 2020-09-30 | 59.62% | +3.62 pp |
| Q2 2020 | 2020-06-30 | 59.45% | +3.11 pp |
| Q1 2020 | 2020-03-31 | 57.94% | +5.18 pp |
| Q4 2019 | 2019-12-31 | 57.03% | +5.07 pp |
| Q3 2019 | 2019-09-30 | 55.99% | +2.29 pp |
| Q2 2019 | 2019-06-30 | 56.34% | +7.05 pp |
| Q1 2019 | 2019-03-31 | 52.76% | +4.99 pp |
| Q4 2018 | 2018-12-31 | 51.96% | +16.77 pp |
| Q3 2018 | 2018-09-30 | 53.71% | +5.79 pp |
| Q2 2018 | 2018-06-30 | 49.29% | −0.71 pp |
| Q1 2018 | 2018-03-31 | 47.77% | +22.25 pp |
| Q4 2017 | 2017-12-30 | 35.19% | +5.21 pp |
| Q3 2017 | 2017-09-30 | 47.91% | +15.74 pp |
| Q2 2017 | 2017-07-01 | 50.00% | +11.86 pp |
| Q3 2011 | 2011-10-01 | 25.52% | — |
| Q2 2011 | 2011-07-02 | 29.98% | — |
| Q3 2010 | 2010-10-02 | 32.18% | — |
| Q2 2010 | 2010-07-03 | 38.14% | — |
Over the last five reported fiscal years, Niagen Bioscience's gross margin increased from 59.53% to 64.28%, a change of +4.75 percentage points. The latest reported quarter, Q2 2026, shows 64.84%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Niagen Bioscience filings at SEC.gov ↗